Zvinoenderana nezvakabuda mumakore mashanu ekutevera kwePACE kiyi bvunzo yakaburitswa muRondedzero yeHematology, panatinib (Ponatinib, Iclusig) yakachengetedza kwenguva refu mune vanorapwa zvakanyanya vane chisingaperi chisingaperi chisingaperi myeloid leukemia (CP-CML) reaction.
Paavhareji yekutevera kwemwedzi makumi mashanu nematanhatu, 56.8% (n = 60) yevarwere 159 vanoongororwa vakawana mhinduro huru yemaseru (MCyR). 54% (n = 144) yevarwere vaive nemhinduro yakakwana yemaseru. 40% (n = 108) patients achieved a major molecular response (MMR), and 24% (n = 64) achieved a molecular response. During the median follow-up period, at 12 months, 82% of patients achieved MCyR, and at 5 years, an estimated 59% of patients achieved MMR. The most common (≥40%) adverse events (TEAE) were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%) and constipation (41%).
In the entire 270 patient cohort, more than 90% of patients had received at least 2 TKI treatments. Investigators found that the response was related to long-term results. The 5-year progression-free survival (PFS) is expected to be 53%, and the overall survival (OS) is 73%.
Kuburitswa kweiyi data chinhu chakakosha nekuti zvinoratidza kuti Ponatinib ichiri nzira yekurapa inoshanda kune varwere vakakodzera vane yapfuura TKI kutadza (kusanganisira varwere vane T315I mutation).
